Related Experiment Video

Updated: Jul 5, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential

Anthony Scimè1, Michael A Rudnicki

  • 1Regenerative Medicine Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada.

Molecular Diagnosis & Therapy
|April 22, 2008
PubMed

Insights

Duchenne muscular dystrophy (DMD) treatments have improved lifespan, but a cure remains elusive. Gene and cellular therapies show promise for treating this genetic muscle-wasting disease.

Area of Science:

  • Genetics
  • Neurology
  • Regenerative Medicine

Background:

  • Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder causing progressive muscle degeneration.
  • Advances in multidisciplinary care have extended patient lifespan, yet a cure is not yet available.
  • Current treatments do not prevent progressive disability or premature death in adulthood.

Purpose of the Study:

  • To review the current state of gene and cellular therapy for Duchenne muscular dystrophy.
  • To highlight the progress and challenges in developing curative treatments for DMD.
  • To identify future research directions for managing and curing DMD.

Main Methods:

  • Review of current viral and nonviral gene therapy strategies for DMD.
  • Analysis of adeno-associated virus (AAV) vectors, naked plasmid DNA, antisense oligonucleotides, and gene editing techniques.
  • Evaluation of research transitioning from preclinical to clinical settings.

Main Results:

  • Gene and cellular therapies have advanced significantly, moving into clinical trials.
  • Various sophisticated gene therapy approaches are under investigation for DMD.
  • Despite progress, existing therapies still have limitations and require further development.

Conclusions:

  • Cellular and gene therapies represent the most promising avenue for a Duchenne muscular dystrophy cure.
  • Continued research is essential to overcome current therapeutic challenges and develop effective strategies.
  • The ultimate goal is to devise treatments that can manage and potentially cure DMD, improving long-term outcomes.

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...